Clinical trial · Interventional
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Early Detection of Complications During Immunotherapy for Haematological Malignancy - Description of Associated Vital Signs and Immune Responses
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CRS - Cytokine Release Syndrome | — | UNRESOLVED | — |
| Hematologic Cancer | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| WARD | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- WARD equipment alarms
- description
- alarms will notify the health personel that there is an abnormal vital sign, and the personel will act accordingly.
- interventionNames
- Device: WARD
Primary outcomes (1)
- measure
- occurrence of cytokine release syndrom
- timeFrame
- 30 days
- description
- After treatment, grade 1 or above (see definitions under "study description")
Secondary outcomes (3)
- measure
- Immune response
- timeFrame
- 30 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma) * Patients scheduled for treatment with CART or BsAbs Exclusion Criteria: * Patient is pregnant * Patient has a pacemaker * Patient is allergic to one or more of the materials that the equipment consists of * Investigator deems patient not able to comply with participation in the study
References
Publications (0)
Data not yet available